Nick Pavlakis

605 total citations
18 papers, 169 citations indexed

About

Nick Pavlakis is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Nick Pavlakis has authored 18 papers receiving a total of 169 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 4 papers in Epidemiology. Recurrent topics in Nick Pavlakis's work include Colorectal Cancer Treatments and Studies (7 papers), Pancreatic and Hepatic Oncology Research (5 papers) and Neuroendocrine Tumor Research Advances (4 papers). Nick Pavlakis is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Pancreatic and Hepatic Oncology Research (5 papers) and Neuroendocrine Tumor Research Advances (4 papers). Nick Pavlakis collaborates with scholars based in Australia, Canada and New Zealand. Nick Pavlakis's co-authors include Michael P. Ward, Grace Chojnowski, Matthew Burge, Amanda C. Stanley, Michael P. Brown, Nigel J. Waterhouse, Lucie Leveque, Charlotte Lemech, David Goldstein and Andrew D. Clouston and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Nick Pavlakis

16 papers receiving 168 citations

Peers

Nick Pavlakis

ONCOL

CCM

PRM

RNMI

SURGE

Ilaria Depetris Italy

Cristina Madaudo Italy

Merna Armanious United States

Naomi Dempsey United States

Wafaa Elatre United States

Naoki Tashiro Japan

Fiona Langlands United Kingdom

Daniele Lorenzini Italy

José María Serrano Antolín Spain

Luc Vittori United States

Ilaria Depetris Italy

Nick Pavlakis

119 ×1.3

ONCOL

50 ×0.6

CCM

42 ×1.2

PRM

12 ×0.5

RNMI

16 ×0.7

SURGE

Citations per year, relative to Nick Pavlakis Nick Pavlakis (= 1×) peers Ilaria Depetris

Countries citing papers authored by Nick Pavlakis

Since Specialization

Citations

This map shows the geographic impact of Nick Pavlakis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nick Pavlakis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nick Pavlakis more than expected).

Fields of papers citing papers by Nick Pavlakis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nick Pavlakis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nick Pavlakis. The network helps show where Nick Pavlakis may publish in the future.

Co-authorship network of co-authors of Nick Pavlakis

This figure shows the co-authorship network connecting the top 25 collaborators of Nick Pavlakis. A scholar is included among the top collaborators of Nick Pavlakis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nick Pavlakis. Nick Pavlakis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Goldstein, David S., Katrin Marie Sjoquist, Sun Young Rha, et al.. (2025). LBA80 Regorafenib plus nivolumab vs investigator’s choice of chemotherapy in previously treated gastric or gastroesophageal cancer: INTEGRATE IIb, a randomized phase 3 AGITG Intergroup [NHMRC-CTC/IKF/AIO, ACCRU, TCOG/NHRI] study. Annals of Oncology. 36. S1622–S1623.

Burns, Christopher J., Terrie‐Anne Cock, Anthony C. Bishop, et al.. (2024). Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial): Interim analysis.. Journal of Clinical Oncology. 42(16_suppl). e16337–e16337. 1 indexed citations

Bernard, Elizabeth J., Dale L. Bailey, Paul Roach, et al.. (2024). Metabolic Tumor Volume on 18-Fluorodeoxyglucose Positron Emission Tomography as a Prognostic Marker of Survival in Patients With Locally Advanced or Metastatic Neuroendocrine Neoplasms Treated With 177Lutetium-DOTA-Octreotate Peptide Receptor Radionuclide Therapy. Pancreas. 53(7). e560–e565. 1 indexed citations

McKay, Matthew J., Malinda Itchins, Nick Pavlakis, et al.. (2024). Therapeutic drug monitoring of osimertinib in EGFR mutant non‐small cell lung cancer by dried blood spot and plasma collection: A pilot study. British Journal of Clinical Pharmacology. 90(8). 1942–1951. 2 indexed citations

Pavlakis, Nick, et al.. (2024). 1272P Updated results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET tri-specific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). Annals of Oncology. 35. S813–S813. 1 indexed citations

Cock, Terrie‐Anne, Anthony C. Bishop, Marion Harris, et al.. (2024). Abstract CT220: Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel (Abraxane) standard of care as first-line therapy in patients with advanced pancreatic cancer (ACCENT trial): interim analysis. Cancer Research. 84(7_Supplement). CT220–CT220. 2 indexed citations

Sahni, Sumit, Christopher B. Nahm, Mahsa Ahadi, et al.. (2023). Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy. Cancer Medicine. 12(17). 18050–18061. 4 indexed citations

Lemech, Charlotte, Keith Dredge, Edward Hammond, et al.. (2023). Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors. Journal for ImmunoTherapy of Cancer. 11(1). e006136–e006136. 26 indexed citations

Pavlakis, Nick, Kohei Shitara, Katrin Marie Sjoquist, et al.. (2023). INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG).. Journal of Clinical Oncology. 41(4_suppl). LBA294–LBA294. 13 indexed citations

10.

Goldstein, David, Eva Segelov, Nick Pavlakis, et al.. (2022). The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours. Targeted Oncology. 17(2). 95–110. 3 indexed citations

11.

Mileshkin, Linda, Jaclyn Yoong, Jennifer Philip, et al.. (2022). PEARL: A randomised phase 3 trial of palliative care early in advanced lung cancers (ALTG/TOGA 13/008).. Journal of Clinical Oncology. 40(16_suppl). 12020–12020. 1 indexed citations

12.

Joseph, Joseph, et al.. (2022). Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta‐analysis. Asia-Pacific Journal of Clinical Oncology. 18(6). 526–539. 5 indexed citations

13.

Redman, Jason M., Milind Javle, Karen Kelly, et al.. (2022). P-133 Clinical responses in pancreaticobiliary cancer patients who received bintrafusp alfa (BA) or BA plus CXCR1/2 inhibitor (SX-682) plus CEA/MUC1-targted vaccine (CV301). Annals of Oncology. 33. S297–S297. 2 indexed citations

14.

Segelov, Eva, David Chan, Ben Lawrence, et al.. (2016). Identifying and Prioritizing Gaps in Neuroendocrine Tumor Research: A Modified Delphi Process With Patients and Health Care Providers to Set the Research Action Plan for the Newly Formed Commonwealth Neuroendocrine Tumor Collaboration. Journal of Global Oncology. 3(4). 380–388. 6 indexed citations

15.

Singh, Simron, Ben Lawrence, David Chan, Nick Pavlakis, & Eva Segelov. (2016). CommNETS: Formation of an International Commonwealth countries NET partnership. 1 indexed citations

16.

Barbour, Andrew P., Nicholas O’Rourke, Manju D. Chandrasegaram, et al.. (2015). A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study.. Journal of Clinical Oncology. 33(15_suppl). 4115–4115. 4 indexed citations

17.

Davis, Ian D., A. Long, Andrew Martin, et al.. (2014). EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901).. Journal of Clinical Oncology. 32(4_suppl). 438–438. 1 indexed citations

18.

Pavlakis, Nick, et al.. (2010). Cardiotoxicity with 5‐fluorouracil and capecitabine: more than just vasospastic angina. Internal Medicine Journal. 40(4). 303–307. 96 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact